8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 19, 2026·SEC
Material company update
Jan 8, 2026·SEC
Ardelyx, Inc.(ARDX)Earnings, Financials & Key Ratios
ARDX•NASDAQ
$7.13
$1.75B mkt cap·Price updated May 6, 2026
AboutArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$407M+22.1%
- EBITDA-$38M-46.5%
- Net Income-$62M-57.4%
- EPS (Diluted)-0.26-52.9%
- Gross Margin89.54%+5.5%
- EBITDA Margin-9.31%-20.0%
- Operating Margin-10.06%-20.1%
- Net Margin-15.12%-28.9%
- ROE-36.21%-57.3%
- ROIC-10.74%-18.6%
- Debt/Equity1.27+43.1%
- Interest Coverage-1.44-54.4%
ARDX Key Insights
Ardelyx, Inc. (ARDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 121.9%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Expensive at 10.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARDX Price & Volume
Ardelyx, Inc. (ARDX) stock price & volume — 10-year historical chart
Loading chart...
ARDX Growth Metrics
Ardelyx, Inc. (ARDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years32.72%
5 Years121.9%
3 Years98.4%
TTM18.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4.77%
Return on Capital
10 Years-48.82%
5 Years-45.14%
3 Years-17.97%
Last Year-10.63%
ARDX Recent Earnings
Ardelyx, Inc. (ARDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026EPS
$0.15
Est $0.13
-15.4%
Revenue
$94M
Est $93M
+1.8%
Q1 2026
Feb 19, 2026EPS
$0.02
Est $0.02
+0.0%
Revenue
$125M
Est $118M
+6.1%
Q4 2025
Oct 30, 2025EPS
$0.00
Est $0.06
+93.3%
Revenue
$110M
Est $119M
-7.3%
Q3 2025
Aug 4, 2025EPS
$0.08
Est $0.13
+38.5%
Revenue
$98M
Est $95M
+3.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.15vs $0.13-15.4% | $94Mvs $93M+1.8% |
| Q1 2026 | Feb 19, 2026 | $0.02vs $0.02+0.0% | $125Mvs $118M+6.1% |
| Q4 2025 | Oct 30, 2025 | $0.00vs $0.06+93.3% | $110Mvs $119M-7.3% |
| Q3 2025 | Aug 4, 2025 | $0.08vs $0.13+38.5% | $98Mvs $95M+3.2% |
Based on last 12 quarters of dataView full earnings history →
ARDX Peer Comparison
Ardelyx, Inc. (ARDX) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CYCN | 13.64M | 3.15 | -2.89 | 3.7% | -170.11% | -39.23% | ||
 CHRS | 216.87M | 1.79 | 1.25 | -84.2% | 398.43% | 7.89% | 0.02 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 INVA | 1.69B | 22.65 | 6.86 | 18.52% | 65.38% | 23.12% | 11.58% | |
 SUPN | 2.82B | 49.03 | -72.10 | 8.63% | -3.74% | -2.73% | 1.63% | 0.04 |
 ASRT | 142.31M | 22.16 | -4.68 | -5% | -24.85% | -29.39% | 0.42 | |
 VKTX | 3.63B | 31.31 | -9.82 | -71.31% | 0.00 | |||
 AGIO | 1.62B | 27.21 | -3.82 | 48.03% | -6.4% | -34.11% | 0.05 |
Compare ARDX vs Peers
Ardelyx, Inc. (ARDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARDX Income Statement
Ardelyx, Inc. (ARDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 42M | 2.61M | 5.28M | 7.57M | 10.1M | 52.16M | 124.46M | 333.62M | 407.32M | 427.68M |
| Revenue Growth % | 74.81% | -93.79% | 102.57% | 43.36% | 33.36% | 416.57% | 138.61% | 168.06% | 22.09% | 18.24% |
| Cost of Goods Sold | 8.4M | 466K | 600K | 145K | 1M | 4.12M | 17.8M | 50.56M | 42.6M | 34.5M |
| COGS % of Revenue | 20% | 17.88% | 11.36% | 1.92% | 9.9% | 7.89% | 14.3% | 15.15% | 10.46% | - |
| Gross Profit | 33.6M▲ 0% | 2.14M▼ 93.6% | 4.68M▲ 118.6% | 7.43M▲ 58.6% | 9.1M▲ 22.5% | 48.04M▲ 428.1% | 106.66M▲ 122.0% | 283.06M▲ 165.4% | 364.72M▲ 28.9% | 393.18M▲ 0% |
| Gross Margin % | 80% | 82.13% | 88.64% | 98.08% | 90.1% | 92.11% | 85.7% | 84.85% | 89.54% | 91.93% |
| Gross Profit Growth % | 47.82% | -93.63% | 118.64% | 58.64% | 22.5% | 428.1% | 122.02% | 165.38% | 28.85% | - |
| Operating Expenses | 98.72M | 93.09M | 95.94M | 98.21M | 163.44M | 111.8M | 169.94M | 311.01M | 405.7M | 430.6M |
| OpEx % of Revenue | 235.04% | 3570.69% | 1816.78% | 1297.13% | 1618.73% | 214.35% | 136.54% | 93.22% | 99.6% | - |
| Selling, General & Admin | 23.23M | 23.71M | 24.27M | 33.15M | 72.3M | 76.6M | 134.4M | 258.69M | 337.23M | 356.28M |
| SG&A % of Revenue | 55.31% | 909.67% | 459.52% | 437.89% | 716.08% | 146.86% | 107.99% | 77.54% | 82.79% | - |
| Research & Development | 75.48M | 69.37M | 71.68M | 65.05M | 91.14M | 35.2M | 35.54M | 52.32M | 68.47M | 74.32M |
| R&D % of Revenue | 179.72% | 2661.03% | 1357.26% | 859.24% | 902.64% | 67.49% | 28.55% | 15.68% | 16.81% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -65.11M▲ 0% | -90.95M▼ 39.7% | -91.26M▼ 0.3% | -90.78M▲ 0.5% | -154.35M▼ 70.0% | -63.76M▲ 58.7% | -63.28M▲ 0.8% | -27.95M▲ 55.8% | -40.98M▼ 46.6% | -37.42M▲ 0% |
| Operating Margin % | -155.04% | -3488.57% | -1728.14% | -1199.05% | -1528.63% | -122.24% | -50.84% | -8.38% | -10.06% | -8.75% |
| Operating Income Growth % | 42.32% | -39.67% | -0.35% | 0.53% | -70.02% | 58.69% | 0.76% | 55.83% | -46.61% | - |
| EBITDA | -62.48M | -88.27M | -86.92M | -86.81M | -151.54M | -62.62M | -61.98M | -25.89M | -37.92M | -34.96M |
| EBITDA Margin % | -148.75% | -3385.85% | -1645.96% | -1146.6% | -1500.83% | -120.05% | -49.8% | -7.76% | -9.31% | -8.18% |
| EBITDA Growth % | 44.02% | -41.28% | 1.52% | 0.13% | -74.57% | 58.68% | 1.01% | 58.24% | -46.48% | 6.49% |
| D&A (Non-Cash Add-back) | 2.64M | 2.68M | 4.34M | 3.97M | 2.81M | 1.14M | 1.29M | 2.06M | 3.06M | 2.46M |
| EBIT | -63.16M | -87.76M | -88.91M | -89.21M | -153.66M | -62.13M | -56.65M | -18.78M | -40.98M | -4.63M |
| Net Interest Income | 0 | -3.53M | -5.73M | -5.1M | -4.5M | -5.07M | -8.87M | -20.09M | -28.4M | -22.14M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 3.53M | 5.73M | 5.1M | 4.5M | 5.07M | 8.87M | 20.09M | 28.4M | 16.54M |
| Other Income/Expense | 1.96M | -347K | -3.37M | -3.53M | -3.81M | -3.44M | -2.24M | -10.92M | -19.65M | -20.52M |
| Pretax Income | -63.16M▲ 0% | -91.29M▼ 44.5% | -94.64M▼ 3.7% | -94.31M▲ 0.3% | -158.16M▼ 67.7% | -67.2M▲ 57.5% | -65.52M▲ 2.5% | -38.87M▲ 40.7% | -60.63M▼ 56.0% | -57.94M▲ 0% |
| Pretax Margin % | -150.38% | -3501.88% | -1792.03% | -1245.69% | -1566.42% | -128.84% | -52.65% | -11.65% | -14.89% | -13.55% |
| Income Tax | 1.18M | 4K | 303K | 2K | 4K | 8K | 547K | 266K | 969K | 118K |
| Effective Tax Rate % | -1.87% | -0% | -0.32% | -0% | -0% | -0.01% | -0.83% | -0.68% | -1.6% | -0.2% |
| Net Income | -64.34M▲ 0% | -91.3M▼ 41.9% | -94.94M▼ 4.0% | -94.31M▲ 0.7% | -158.16M▼ 67.7% | -67.21M▲ 57.5% | -66.07M▲ 1.7% | -39.14M▲ 40.8% | -61.6M▼ 57.4% | -58.06M▲ 0% |
| Net Margin % | -153.19% | -3502.03% | -1797.77% | -1245.71% | -1566.46% | -128.85% | -53.08% | -11.73% | -15.12% | -13.58% |
| Net Income Growth % | 42.75% | -41.9% | -3.99% | 0.66% | -67.7% | 57.51% | 1.7% | 40.76% | -57.4% | -7.99% |
| Net Income (Continuing) | -64.34M | -91.3M | -94.94M | -94.31M | -158.16M | -67.21M | -66.07M | -39.14M | -61.6M | -58.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.36▲ 0% | -1.62▼ 19.1% | -1.47▲ 9.3% | -1.05▲ 28.6% | -1.52▼ 44.8% | -0.42▲ 72.4% | -0.30▲ 28.6% | -0.17▲ 43.3% | -0.26▼ 52.9% | -0.24▲ 0% |
| EPS Growth % | 51.43% | -19.12% | 9.26% | 28.57% | -44.76% | 72.37% | 28.57% | 43.33% | -52.94% | -4.77% |
| EPS (Basic) | -1.36 | -1.62 | -1.47 | -1.05 | -1.52 | -0.42 | -0.30 | -0.17 | -0.26 | - |
| Diluted Shares Outstanding | 47.44M | 56.22M | 64.48M | 89.58M | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M | 245.86M |
| Basic Shares Outstanding | 47.44M | 56.22M | 64.48M | 89.58M | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M | 245.86M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARDX Balance Sheet
Ardelyx, Inc. (ARDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 149.87M | 177.72M | 252.38M | 195.24M | 133.65M | 153.6M | 246.11M | 356.45M | 382.32M | 381.87M |
| Cash & Short-Term Investments | 133.98M | 168.09M | 247.51M | 186.48M | 116.69M | 123.91M | 184.3M | 250.1M | 264.69M | 238.07M |
| Cash Only | 75.38M | 78.77M | 181.13M | 91.03M | 72.43M | 96.14M | 21.47M | 64.93M | 68M | 31.21M |
| Short-Term Investments | 58.59M | 89.32M | 66.38M | 95.45M | 44.26M | 27.77M | 162.83M | 185.17M | 196.69M | 206.87M |
| Accounts Receivable | 10.8M | 5.08M | 750K | 0 | 502K | 7.73M | 22.03M | 57.7M | 71.85M | 82.84M |
| Days Sales Outstanding | 93.82 | 711.94 | 51.84 | - | 18.15 | 54.12 | 64.61 | 63.13 | 64.38 | 62.7 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.28M | 12.45M | 21.17M | 17.73M | 22.75M |
| Days Inventory Outstanding | - | - | - | - | - | 290.97 | 255.33 | 152.86 | 151.97 | 232.55 |
| Other Current Assets | 0 | 0 | 0 | 0 | 1 | 5.11M | 8.41M | 11.1M | 28.05M | 38.21M |
| Total Non-Current Assets | 8.03M | 5.61M | 7.41M | 6.32M | 16.26M | 36.46M | 51.47M | 79.3M | 119.29M | 122.64M |
| Property, Plant & Equipment | 8.03M | 5.61M | 7.41M | 4.21M | 15.11M | 10.52M | 6.6M | 3.88M | 6.98M | 6.43M |
| Fixed Asset Turnover | 5.23x | 0.46x | 0.71x | 1.80x | 0.67x | 4.96x | 18.86x | 86.09x | 58.36x | 61.57x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 2.11M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 1.15M | 25.95M | 44.87M | 75.43M | 112.31M | 447.53M |
| Total Assets | 157.9M▲ 0% | 183.33M▲ 16.1% | 259.78M▲ 41.7% | 201.56M▼ 22.4% | 149.91M▼ 25.6% | 190.07M▲ 26.8% | 297.58M▲ 56.6% | 435.75M▲ 46.4% | 501.6M▲ 15.1% | 504.51M▲ 0% |
| Asset Turnover | 0.27x | 0.01x | 0.02x | 0.04x | 0.07x | 0.27x | 0.42x | 0.77x | 0.81x | 0.87x |
| Asset Growth % | -25.91% | 16.1% | 41.7% | -22.41% | -25.62% | 26.78% | 56.57% | 46.43% | 15.11% | 106.43% |
| Total Current Liabilities | 17.87M | 17.73M | 22.22M | 28.42M | 52.82M | 65.6M | 50.39M | 77.83M | 88.61M | 109.57M |
| Accounts Payable | 3.93M | 1.15M | 2.19M | 5.63M | 4.28M | 10.86M | 11.14M | 16M | 19.23M | 28.2M |
| Days Payables Outstanding | 170.9 | 899.18 | 1.33K | 14.16K | 1.56K | 962.72 | 228.46 | 115.52 | 164.82 | 231.43 |
| Short-Term Debt | 0 | 0 | 3.79M | 6.28M | 32.26M | 26.71M | 0 | 0 | 1.48M | 1.51M |
| Deferred Revenue (Current) | 0 | 1M | 4.54M | 4.18M | 0 | 4.21M | 7.18M | 10.69M | 1.21M | 17.32M |
| Other Current Liabilities | 10.71M | 12.86M | 4.64M | 5.22M | 1.24M | 10.09M | 15.04M | 49.58M | 66.69M | 76.61M |
| Current Ratio | 8.39x | 10.02x | 11.36x | 6.87x | 2.53x | 2.34x | 4.88x | 4.58x | 4.31x | 4.31x |
| Quick Ratio | 8.39x | 10.02x | 11.36x | 6.87x | 2.53x | 2.29x | 4.64x | 4.31x | 4.11x | 4.11x |
| Cash Conversion Cycle | - | - | - | - | - | -617.64 | 91.48 | 100.48 | 51.53 | 63.81 |
| Total Non-Current Liabilities | 720K | 49.79M | 50.91M | 47.03M | 14.47M | 26.13M | 80.37M | 184.63M | 246.05M | 246.32M |
| Long-Term Debt | 0 | 49.21M | 48.83M | 46.62M | 0 | 0 | 49.82M | 150.85M | 206.47M | 206.75M |
| Capital Lease Obligations | 0 | 0 | 2.08M | 413K | 9.75M | 5.86M | 1.73M | 1.02M | 3.64M | 11.69M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.2M |
| Other Non-Current Liabilities | 720K | 582K | 0 | 0 | 4.73M | 11.25M | 20.18M | 25.53M | -3.64M | 92.31M |
| Total Liabilities | 18.59M | 67.52M | 73.13M | 75.45M | 67.3M | 91.74M | 130.76M | 262.46M | 334.65M | 355.88M |
| Total Debt | 0 | 49.21M | 57.31M | 55.44M | 45.5M | 36.46M | 55.98M | 153.44M | 211.59M | 208.26M |
| Net Debt | -75.38M | -29.56M | -123.83M | -35.6M | -26.92M | -59.68M | 34.51M | 88.51M | 143.6M | 177.06M |
| Debt / Equity | - | 0.42x | 0.31x | 0.44x | 0.55x | 0.37x | 0.34x | 0.89x | 1.27x | 1.27x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.96x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.06x |
| Interest Coverage | - | -24.83x | -15.53x | -17.50x | -34.13x | -12.25x | -6.38x | -0.93x | -1.44x | -0.28x |
| Total Equity | 139.31M▲ 0% | 115.81M▼ 16.9% | 186.66M▲ 61.2% | 126.11M▼ 32.4% | 82.62M▼ 34.5% | 98.33M▲ 19.0% | 166.82M▲ 69.7% | 173.29M▲ 3.9% | 166.95M▼ 3.7% | 148.62M▲ 0% |
| Equity Growth % | -27.87% | -16.87% | 61.17% | -32.44% | -34.49% | 19.02% | 69.65% | 3.88% | -3.66% | -9.25% |
| Book Value per Share | 2.94 | 2.06 | 2.89 | 1.41 | 0.79 | 0.62 | 0.76 | 0.74 | 0.69 | 0.60 |
| Total Shareholders' Equity | 139.31M | 115.81M | 186.66M | 126.11M | 82.62M | 98.33M | 166.82M | 173.29M | 166.95M | 148.62M |
| Common Stock | 5K | 6K | 9K | 9K | 13K | 20K | 23K | 24K | 24K | 25K |
| Retained Earnings | -278.21M | -365.51M | -460.45M | -554.76M | -712.93M | -780.14M | -846.2M | -885.34M | -946.94M | -984.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -47K | -38K | 20K | -4K | -6K | -54K | 224K | 57K | 198K | -124K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARDX Cash Flow Statement
Ardelyx, Inc. (ARDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -65.19M | -70.27M | -76.48M | -81.44M | -152.55M | -70.04M | -89.72M | -44.81M | -42.48M | -42.48M |
| Operating CF Margin % | -155.21% | -2695.59% | -1448.29% | -1075.62% | -1510.85% | -134.29% | -72.09% | -13.43% | -10.43% | - |
| Operating CF Growth % | 29.55% | -7.8% | -8.84% | -6.47% | -87.33% | 54.08% | -28.09% | 50.06% | 5.19% | 71.95% |
| Net Income | -64.34M | -91.3M | -94.94M | -94.31M | -158.16M | -67.21M | -66.07M | -39.14M | -61.6M | -58.06M |
| Depreciation & Amortization | 2.64M | 2.68M | 2.5M | 1.82M | 1.44M | 1.14M | 1.29M | 2.06M | 3.06M | 3.37M |
| Stock-Based Compensation | 9.59M | 9.23M | 9.94M | 10.58M | 12.04M | 10.75M | 13.53M | 37.38M | 48.96M | 38.59M |
| Deferred Taxes | 11K | -1.02M | -262K | 315K | -190K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 567K | 792K | 3.3M | 3.37M | 4.25M | 4.84M | 4.91M | 4.05M | -1.55M | 8.06M |
| Working Capital Changes | -13.66M | 9.35M | 2.98M | -3.21M | -11.92M | -19.57M | -43.39M | -49.17M | -31.35M | -28.23M |
| Change in Receivables | -10.8M | 10.71M | 85K | 750K | -502K | -7.23M | -14.3M | -35.67M | -14.14M | -36.37M |
| Change in Inventory | -1.9M | 1.88M | -3.41M | -750K | -10.37M | -28.35M | -21.14M | -41.7M | -31.92M | -22.15M |
| Change in Payables | -1.03M | -2.73M | 39K | 3.44M | -1.35M | 6.58M | 279K | 4.86M | 3.23M | 14.47M |
| Cash from Investing | 65.29M | -29.89M | 23.37M | -31.44M | 50.95M | 18.41M | -131.25M | -18.32M | -8.96M | -21.8M |
| Capital Expenditures | -2.35M | -311K | -325K | -324K | -1.87M | -55K | -344K | -1.01M | -1.49M | -1.24M |
| CapEx % of Revenue | 5.61% | 11.93% | 6.15% | 4.28% | 18.49% | 0.11% | 0.28% | 0.3% | 0.37% | - |
| Acquisitions | 0 | 0 | -23.7M | 31.44M | -52.81M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 67.64M | -29.58M | 23.7M | -31.44M | 52.81M | 1.8M | 0 | 0 | 0 | 0 |
| Cash from Financing | 685K | 103.55M | 155.48M | 22.78M | 83M | 75.34M | 146.29M | 106.59M | 54.51M | 58.47M |
| Debt Issued (Net) | 0 | 49.29M | 0 | -125K | -19.44M | -6.07M | 22.39M | 99.45M | 48.67M | 48.67M |
| Equity Issued (Net) | 0 | 53.77M | 154.9M | 21.05M | 101.15M | 71.63M | 119.24M | 8.14M | 5.84M | 9.8M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 685K | 491K | 574K | 1.85M | 1.3M | 9.78M | 4.67M | -1M | 0 | 0 |
| Net Change in Cash | 785K▲ 0% | 3.38M▲ 331.2% | 102.36M▲ 2924.1% | -90.1M▼ 188.0% | -18.6M▲ 79.4% | 23.71M▲ 227.5% | -74.67M▼ 414.9% | 43.46M▲ 158.2% | 3.07M▼ 92.9% | 401K▲ 0% |
| Free Cash Flow | -67.55M▲ 0% | -70.58M▼ 4.5% | -76.81M▼ 8.8% | -81.76M▼ 6.4% | -154.42M▼ 88.9% | -70.1M▲ 54.6% | -90.06M▼ 28.5% | -45.82M▲ 49.1% | -43.98M▲ 4.0% | -37.5M▲ 0% |
| FCF Margin % | -160.82% | -2707.52% | -1454.44% | -1079.9% | -1529.35% | -134.4% | -72.36% | -13.73% | -10.8% | -8.77% |
| FCF Growth % | 30.65% | -4.5% | -8.82% | -6.44% | -88.87% | 54.6% | -28.48% | 49.12% | 4.03% | 23.05% |
| FCF per Share | -1.42 | -1.26 | -1.19 | -0.91 | -1.48 | -0.44 | -0.41 | -0.19 | -0.18 | -0.18 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.77x | 0.81x | 0.86x | 0.96x | 1.04x | 1.36x | 1.14x | 0.69x | 0.65x |
| Interest Paid | 0 | 0 | 4.92M | 4.2M | 3.47M | 2.9M | 4.24M | 11.41M | 0 | 8.4M |
| Taxes Paid | 3K | 4K | 2K | 1K | 4K | 6K | 51K | 266K | 0 | 489K |
ARDX Key Ratios
Ardelyx, Inc. (ARDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -38.7% | -71.57% | -62.78% | -60.31% | -151.55% | -74.28% | -49.83% | -23.01% | -36.21% | -38.11% |
| Return on Invested Capital (ROIC) | -53.52% | -90.84% | -91.83% | -88.8% | -158.35% | -101.37% | -39.55% | -9.05% | -10.74% | -10.74% |
| Gross Margin | 80% | 82.13% | 88.64% | 98.08% | 90.1% | 92.11% | 85.7% | 84.85% | 89.54% | 91.93% |
| Net Margin | -153.19% | -3502.03% | -1797.77% | -1245.71% | -1566.46% | -128.85% | -53.08% | -11.73% | -15.12% | -13.58% |
| Debt / Equity | - | 0.42x | 0.31x | 0.44x | 0.55x | 0.37x | 0.34x | 0.89x | 1.27x | 1.27x |
| Interest Coverage | - | -24.83x | -15.53x | -17.50x | -34.13x | -12.25x | -6.38x | -0.93x | -1.44x | -0.28x |
| FCF Conversion | 1.01x | 0.77x | 0.81x | 0.86x | 0.96x | 1.04x | 1.36x | 1.14x | 0.69x | 0.65x |
| Revenue Growth | 74.81% | -93.79% | 102.57% | 43.36% | 33.36% | 416.57% | 138.61% | 168.06% | 22.09% | 18.24% |
ARDX SEC Filings & Documents
Ardelyx, Inc. (ARDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARDX Frequently Asked Questions
Ardelyx, Inc. (ARDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ardelyx, Inc. (ARDX) reported $427.7M in revenue for fiscal year 2025. This represents a 7805% increase from $5.4M in 2012.
Ardelyx, Inc. (ARDX) grew revenue by 22.1% over the past year. This is strong growth.
Ardelyx, Inc. (ARDX) reported a net loss of $58.1M for fiscal year 2025.
Dividend & Returns
Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -36.2%. Negative ROE indicates the company is unprofitable.
Ardelyx, Inc. (ARDX) had negative free cash flow of $37.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More ARDX
Ardelyx, Inc. (ARDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates